ReWalk Robotics Ltd. says its soft exosuit technology currently in development has entered the next phase of testing and verification in collaboration with researchers at Harvard University’s Wyss Institute for Biologically Inspired Engineering.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk’s technology is designed for use by stroke survivors with lower limb disability.
In 2016, ReWalk announced a collaboration with the Wyss Institute to support ongoing technology development and testing of lightweight exoskeleton system concepts and designs for lower limb disabilities and licensed intellectual property (IP) from Harvard University. The soft suit design transmits power to key joints of the legs with cable technologies and fabric-based designs; the soft suit is powered with software and mechanics that are similar to the technologies used in the ReWalk exoskeleton system for individuals with spinal cord injury (SCI).
Soft exoskeleton technology, also called a soft exosuit, is being designed to serve a number of patient populations, including individuals with Multiple Sclerosis, Parkinson’s Disease and other mobility challenges.The newly announced test phase includes evaluating the ReWalk exosuit with individuals who have had a stroke, in preparation for upcoming clinical trials to be run at clinical sites in 2018.
ReWalk CEO Larry Jasinski stated; “Utilization of the technology in an IRB approved research study, ahead of our clinical trials planned for next year, is a key milestone in the larger effort to pursue regulatory approval and eventually offer a commercial product to millions of patients who need ambulatory assistance. We continue to work in earnest on rigorous testing and design modification to develop the best technology for disabled individuals.”
Source: PR Newswire